WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) raised $40.2 million through an at-the-market stock sale after the second quarter, extending its expected cash runway through the end of 2028 …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.